# Drug Development and Delivery: Drug Development and Delivery Magazine

> Drug Development \& Delivery is a print and online publisher that presents the latest scientific methods in drug development for professionals\.

Generated by Yoast SEO v28.5, this is an llms.txt file, meant for consumption by LLMs.

## Pages
- [About Us](https://drug-dev.com/about-us/)
- [Contact](https://drug-dev.com/contact/)
- [Ask AI](https://drug-dev.com/ask-ai/)
- [E\-Books](https://drug-dev.com/e-books/)
- [Advertise Where AI and Pharma Decision\-Makers  Look First](https://drug-dev.com/ai-for-pharma/)

## Posts
- [BIOPHARMA MARKET LAUNCH \- De\-risking Global Market Entry Through Redundant Capacity \& Flexible Manufacturing](https://drug-dev.com/biopharma-market-launch-de-risking-global-market-entry-through-redundant-capacity-flexible-manufacturing/): John Ward and Paul Hamill stress that launch readiness matters as much as development progress\. Thus global expansion is shifting to a near\-term priority and CDMOs can reduce the risk of a global launch through agile downstream execution\.
- [SCHOTT Pharma and Nemera Co\-Develop Integrated 5\.5 mL Syringe and Safety Platform to Advance At\-Home Biologic Delivery](https://drug-dev.com/schott-pharma-and-nemera-co-develop-integrated-5-5-ml-syringe-and-safety-platform-to-advance-at-home-biologic-delivery/)
- [EXECUTIVE INTERVIEW \- Portal Instruments: Beyond Springs – Portal Prime Nexus™ Autoinjector is a Versatile Solution for Biologics](https://drug-dev.com/executive-interview-portal-instruments-beyond-springs-portal-prime-nexus-autoinjector-is-a-versatile-solution-for-biologics/): As biologics become larger, more viscous, and more complex, software offers a fundamentally better way to control and optimize delivery\.
- [Bespak, Upperton Team Up on Integrated Nasal Drug Product Development](https://drug-dev.com/bespak-upperton-team-up-on-integrated-nasal-drug-product-development/)
- [SPECIAL FEATURE \- Injection Devices: Advancements Converge to Expand Patient Possibilities](https://drug-dev.com/special-feature-injection-devices-advancements-converge-to-expand-patient-possibilities/): Cindy H\. Dubin speaks with injection device developers about creating devices that are intelligent, intuitive, patient\-centric systems that make advanced therapies easier, safer, and more accessible to use at home\.

## Videos
- [Oral Peptide Drug Delivery: Overcoming Bioavailability \& Formulation Challenges](https://drug-dev.com/videos/oral-peptide-drug-delivery-overcoming-bioavailability-formulation-challenges/)
- [The Future of Injection Devices: Key Trends Shaping Drug Delivery](https://drug-dev.com/videos/the-future-of-injection-devices-key-trends-shaping-drug-delivery/): Injection devices continue to evolve as pharmaceutical companies look for more effective, convenient, and patient\-focused ways to deliver increasingly complex therapies\.
- [Mastering Analytics: LC\-MS Analysis of Oligonucleotide Drugs](https://drug-dev.com/videos/mastering-analytics-lc-ms-analysis-of-oligonucleotide-drugs/): In this episode of Expert Insights, Drug Development \& Delivery Managing Editor Cindy Dubin speaks with Dr\. Melanie Zerulla\-Wernitz, Head of Analytical Science Laboratory at Vetter, about the growing role of LC\-MS in oligonucleotide characterization\.
- [What Contamination Control Strategy \(CCS\) Means for Customer Confidence in Sterile Manufacturing](https://drug-dev.com/videos/what-contamination-control-strategy-ccs-means-for-customer-confidence-in-sterile-manufacturing/): Contamination Control Strategy \(CCS\) shapes how sterile manufacturers and their suppliers demonstrate control over injectable drug products under Annex 1\. In this video interview, Aptar Pharma's Nicolas Voisin and Audrey Chardonnet explain what CCS means in daily operations, and how it translates into customer confidence\.
- [Small Batches, Big Impact: The New Realities of CDMO Formulation Development](https://drug-dev.com/videos/small-batches-big-impact-the-new-realities-of-cdmo-formulation-development/)

## Webinars
- [WEBINAR \- Challenges of Sustained Release Drug Delivery Devices](https://drug-dev.com/webinars/webinar-challenges-of-sustained-release-drug-delivery-devices/)
- [WEBINAR ON DEMAND \- Heat Without Harm: The Reality of Hot Melt Extrusion Webinar](https://drug-dev.com/webinars/webinar-heat-without-harm-the-reality-of-hot-melt-extrusion-webinar/): In a 2025 industry survey \(1\), 76% of respondents selected 'risk of thermal degradation' as a source of hesitation to pursue hot melt extrusion \(HME\)\. Concerns about heat\-sensitive APIs frequently lead development teams to rule out HME early — often before conducting a thorough scientific evaluation of their formulation options\. 

But thermal risk is frequently overstated\. In this on\-demand webinar, Stefanie Hauck, Senior Director PDS\&T Pharm\. Tech\. at AbbVie Contract Manufacturing, explains why many compounds initially considered unsuitable for HME can be successfully processed with the right expertise\.
- [WEBINAR ON DEMAND: Why early matters: Data\-driven strategies to de\-risk OSD development](https://drug-dev.com/webinars/webinar-on-demand-why-early-matters-data-driven-strategies-to-de-risk-osd-development/): This on\-demand webinar focuses on how data\-driven characterization, predictive modeling, and Quality by Design \(QbD\) approaches help teams identify and address risks earlier—when decisions are more flexible and impacts easier to manage, before scale\-up begins\.
- [ON\-DEMAND WEBINAR: Drug Product Design for Delivery of Challenging Molecules](https://drug-dev.com/webinars/on-demand-webinar-drug-product-design-for-delivery-of-challenging-molecules/): In this talk we illustrate several case studies demonstrating how a fundamental understanding of molecular properties combined with a strategic vision for drug product design can lead to effective and advanceable formulations for even the most challenging drug products\.
- [WEBINAR \- Vytal: The RTU Snap\-Fit System for Container Closure Solutions – Setting the Standard for the Future](https://drug-dev.com/webinars/vytal-the-rtu-snap-fit-system-for-container-closure-solutions-setting-the-standard-for-the-future/): In recent decades, the landscape of parenteral drug production has undergone significant transformation, driven by the emergence of novel molecules and advanced therapies\. The pharmaceutical industry has witnessed a notable shift towards biologics, mAbs, and cell\-based therapies, which now represent some of the most successful pharmaceutical products globally\.

## Whitepapers
- [WHITEPAPER \- Large\-Scale LNP Process Conversions](https://drug-dev.com/whitepapers/whitepaper-large-scale-lnp-process-conversions/)
- [WHITEPAPER \- Streamlined Product Development Leveraging Pharmaceutical Classification Models](https://drug-dev.com/whitepapers/whitepaper-streamlined-product-development-leveraging-pharmaceutical-classification-models/)
- [WHITEPAPER \- Stop Guessing\. Start Predicting: Rethinking Early Oral Drug Development](https://drug-dev.com/whitepapers/white-paper-stop-guessing-start-predicting-rethinking-early-oral-drug-development/): This article explores how AI\-driven predictive insights reduce uncertainty in early oral drug development, enabling smarter decisions on solubility, dosing, stability, and scale\-up while preserving API, accelerating timelines, and de\-risking clinical success \.
- [WHITEPAPER \- Container Closure Integrity Issues in Cell \& Gene Therapy Products](https://drug-dev.com/whitepapers/whitepaper-container-closure-integrity-issues-at-cell-gene-therapy-products/): The cell and gene therapy \(CGT\) product market is expected to grow at a very high rate of around 20\-30% per year over the next 10 years\. Increasing number of approvals, expansion of target diseases, accelerated investment and innovation, and advent of aging population are the key factors for the growth\.
- [WHITEPAPER \- Advancements in Intradermal Delivery: From Historic Techniques to Modern Innovations](https://drug-dev.com/whitepapers/whitepaper-advancements-in-intradermal-delivery-from-historic-techniques-to-modern-innovations/): This white paper explores the evolution of intradermal delivery methods, comparing historic methods of delivery such as the Mantoux technique with modern innovations such as the Terumo Immucise™ Intradermal Injection System\. 

## Company Profiles
- [PCI Pharma Services](https://drug-dev.com/company-profiles/pci-pharma-services/)
- [AbbVie Contract Manufacturing](https://drug-dev.com/company-profiles/abbvie-contract-manufacturing2/)
- [LATITUDE Pharmaceuticals Inc\.](https://drug-dev.com/company-profiles/latitude-pharmaceuticals-inc/)
- [Adare Pharma Solutions](https://drug-dev.com/company-profiles/adare-pharma-solutions/)
- [Bespak](https://drug-dev.com/company-profiles/bespak/)

## Tech Showcase
- [CDMO Services](https://drug-dev.com/tech_showcase/cdmo-services-2/)
- [Contract Development \& Manufacturing](https://drug-dev.com/tech_showcase/contract-development-manufacturing-2/)
- [Pharma Solutions](https://drug-dev.com/tech_showcase/pharma-solutions-2/)
- [Global CRMO](https://drug-dev.com/tech_showcase/global-crmo-2/)
- [CMC Services](https://drug-dev.com/tech_showcase/cmc-services/)

## Video Spotlights
- [Milipore Sigma \- Partek](https://drug-dev.com/video_spotlights/milipore-sigma-partek/)
- [Ajinomoto](https://drug-dev.com/video_spotlights/ajinomoto/)

## Industry Events
- [PDA Universe of Pre\-Filled Syringes and Injection Devices Conference 2026](https://drug-dev.com/industry_events/pda-universe-of-pre-filled-syringes-and-injection-devices-conference-2026/)
- [AAPS PharmSci 360](https://drug-dev.com/industry_events/aaps-pharmsci-360/)
- [CPhI Milan](https://drug-dev.com/industry_events/cphi-milan/)
- [PODD \(Partnership Opportunities in Drug Delivery\)](https://drug-dev.com/industry_events/podd-partnership-opportunities-in-drug-delivery/)

## Issues
- [September 2026](https://drug-dev.com/issues/september-2026/)
- [2026 Sustainable Drug Development \& Delivery eBook](https://drug-dev.com/issues/2026-sustainable-drug-development-delivery-ebook/)
- [Nasal \& Inhalation eBook 2026](https://drug-dev.com/issues/nasal-inhalation-e-book-2026/)
- [June 2026](https://drug-dev.com/issues/june-2026/)
- [May 2026](https://drug-dev.com/issues/may-2026/)

## Expert Content
- [FROM ASSESSMENT TO SUSTAINABLE ACTION \- Circular Economy Strategies \& Practical Routes to Lower\-Impact Medical Devices](https://drug-dev.com/expert-content/from-assessment-to-sustainable-action-circular-economy-strategies-practical-routes-to-lower-impact-medical-devices/): AstraZeneca and Novo Nordisk have both committed to science\-based net\-zero across their full value chains by 2045\. However, decarbonizing manufacturing alone leaves most of the footprint untouched\. Meeting these net\-zero targets requires changes to the products themselves, the devices that deliver them, and the systems built around them, including the reprocessing and reuse networks\. The route to a more sustainable device is not the same for every product, and the single biggest determinant of what is achievable is where a device sits in its product development lifecycle when sustainability is first considered\.
- [Managing Fragmented Small\-Molecule Supply Chains Through Strategic Secondary Bulk Packaging](https://drug-dev.com/expert-content/managing-fragmented-small-molecule-supply-chains-through-strategic-secondary-bulk-packaging/): As small\-molecule manufacturing becomes increasingly fragmented across regions, specialist facilities, and CDMOs, every product handoff introduces new opportunities for delay and variability\. A strategic bulk secondary packaging approach can help standardize product handling, improve operational control, and strengthen resilience across complex pharmaceutical supply chains\.

- [Four Myths About Embedded CMOs, Busted](https://www.abbviecontractmfg.com/news-and-insights/Four-Myths-About-Embedded-CMOs-Busted.html): Are your perceptions of the CMO marketplace serving your drug program—or holding it back? If you’re looking for a contract manufacturer to bring your therapy to market, you’re far from alone\. Demand for manufacturing services is shaping the pharma Contract Manufacturing Industry, with analysts predicting a growth rate of nearly 7% per year until 2028\. In such a competitive market, how should a project sponsor navigate the choice between one CMO and another? To find the answer, many sponsors begin by distinguishing between typical stand\-alone CMOs and an embedded CMO that operates under a parent company—AbbVie, in the case of AbbVie Contract Manufacturing \(AbbVie\)\.
- [How Molecular Biology Technologies Are Transforming Discovery and Development](https://drug-dev.com/expert-content/how-molecular-biology-technologies-are-transforming-discovery-and-development/): Advances in PCR, sequencing, automation, and molecular analysis are helping biopharma teams accelerate discovery, improve data quality, and reduce development risk\. Thermo Fisher Scientific’s Dr\. Anjali Shah discusses how integrated molecular biology workflows are evolving to support increasingly complex therapeutic modalities\.
- [SPECTROSCOPY \- High\-Precision Tunable Laser Spectroscopy: A “Library\-Based” Approach to Quantitative Bioprocess Analytics](https://drug-dev.com/expert-content/spectroscopy-high-precision-tunable-laser-spectroscopy-a-library-based-approach-to-quantitative-bioprocess-analytics/): The accuracy and speed of analytical measurements play a critical role in biopharmaceutical development and manufacturing\. In particular, the ability to quantify both active pharmaceutical ingredients \(APIs\) and formulation excipients – such as buffers, amino acids, sugars, and surfactants – is essential for ensuring product quality, process consistency, and regulatory compliance\.

## Categories
- [Market News \& Trends](https://drug-dev.com/category/market-news-and-trends/)
- [Formulation Development](https://drug-dev.com/category/formulation-development/)
- [Bio Platforms](https://drug-dev.com/category/bio-platforms/)
- [Exclusive Online Content](https://drug-dev.com/category/exclusive-online-content/)
- [Contract Services](https://drug-dev.com/category/contract-services/)

## Optional
- [Sitemap index](https://drug-dev.com/sitemap_index.xml)